Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2017

Open Access 01-12-2017 | Research

Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis

Authors: Ryosuke Nakagawa, Yuji Inoue, Takeshi Ohki, Yuka Kaneko, Fumi Maeda, Masakazu Yamamoto

Published in: World Journal of Surgical Oncology | Issue 1/2017

Login to get access

Abstract

Background

Various types of preoperative chemoradiotherapy (CRT) have been established for rectal cancer; thus,Physicians will need to refine the selection of appropriate preoperative CRT for different patients since there are various treatment regimens. Oral tegafur-uracil (UFT) plus leucovorin (LV) is commonly used to treat rectal cancer in Japan. Oral chemotherapy offers patients many potential advantages. Since 2008, we have been performing preoperative CRT with intermittent oral UFT plus LV in locally advanced rectal cancer patients to prevent postoperative local recurrence. Here, in a retrospective analysis, we evaluated the efficacy and short-term outcomes of preoperative CRT with intermittent oral UFT plus LV.

Methods

We analyzed data from 62 patients with locally advanced rectal cancer, including 31 patients who underwent preoperative CRT between 2009 and 2013 (the CRT group) and 31 patients who were treated with surgery alone between 2001 and 2008 (the non-CRT group). Clinicopathologically, both groups included patients with rectal cancer at clinical tumor stages 3-4 or clinical node stages 0-3. In the CRT group, curative operations were performed ≥8 weeks after CRT. Patients were concomitantly treated with 2 cycles of oral UFT (300 mg/m2/day, days 1–14 and 29–42) plus LV (75 mg/day, days 1–14 and 29–42) and 45 Gy of radiotherapy. Chemotherapy was repeated every 28 days, followed by a 2-week break.

Results

The completion rate of CRT was high at 94% (n = 29/31). The downstaging rate of CRT was 61% (n = 19/31). The pathological complete response rate was 6.5% (n = 2/31). Significant differences were observed in the 3-year local recurrence rate between the two groups (P < 0.05).

Conclusions

Preoperative CRT with intermittent oral UFT plus LV appears to be a tolerable and effective treatment for Japanese patients with rectal cancer. A further investigation of a diversification of preoperative CRT for Japanese rectal cancer patients is required.
Literature
1.
Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health-Syst Pharm. 2007;64(Suppl5):S4–7.CrossRefPubMed
2.
Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomized crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38:349–58.CrossRefPubMed
3.
Liu G, Franssen E, Fitch MI, Warner E. Patients preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–15.CrossRefPubMed
4.
Labianca R, Beretta GD, Mosconi S, Milesi L. The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer. Oncology/Hematology. 2004;52:73–80.CrossRef
5.
6.
Meropol NJ, Rustum YM, Petrelli NJ, Rodriguez-Bigas M, Frank C, Ho DH, et al. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol. 1996;37:581–86.CrossRefPubMed
7.
Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol. 1998;22:333–8.
8.
Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207–39.CrossRefPubMedPubMedCentral
9.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
10.
Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med. 1985; 312:1465–72.
11.
Douglass Jr HO, Moertel CG, Mayer RJ, Thomas PR, Lindblad AS, Mittleman A, et al. Survival afterpostoperative combination treatment of rectal cancer. N Engl J Med. 1986;315:1294–5.CrossRefPubMed
12.
Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.CrossRefPubMed
13.
Gerard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558–65.CrossRefPubMed
14.
O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927–34. doi:10.1200/JCO.2013.53.7753.
15.
Hans-Joachim Schmoll, Karin Haustermans, Timothy Jay Price, Bernard Nordlinger, Ralf Hofheinz, Jean-Francois Daisne, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial. J Clin Oncol. 2013;31(suppl 15):3531. doi:10.1200/jco.2013.31.15_suppl.3531.
16.
Bakogeorgos M, Mountzios G, Kotsantis G, Economopoulou P, Fytrakis N, Kentepozidis N. J BUON. 2013;18(3):629–34.PubMed
17.
de la Torre A, Ramos S, Valcárcel FJ, Candal A, Regueiro CA, Romero J, et al. Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer. Int J Radiat Oncol Biol Phys. 1999;45:629–34.CrossRefPubMed
18.
Fernández-Martos C, Aparicio J, Bosch C, Torregrosa M, Campos JM, Garcera S, et al. Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years’ follow-up. J Clin Oncol. 2004;22:3016–22.CrossRefPubMed
19.
Videtic GM, Fisher BJ, Perera FE, Bauman GS, Kocha WI, Taylor M, et al. Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Int J Radiat Oncol Biol Phys. 1998;42:319–24.CrossRefPubMed
20.
Chen ET, Mohiuddin M, Brodovsky H, Fishbein G, Marks G. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys. 1994;30:169–75.CrossRefPubMed
21.
Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 1999;44:1027–38.CrossRefPubMed
22.
Mehta VK, Poen J, Ford J, Edelstein PS, Vierra M, Bastidas AJ, et al. Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Dis Colon Rectum. 2001;44:52–8.CrossRefPubMed
23.
Ngan SY, Burmeister BH, Fisher R, Rischin D, Schache DJ, Kneebone A, et al. Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2001;50:883–7.CrossRefPubMed
24.
Diaz-Canton E, Pazdur R. Preoperative combined oral UFT plus leucovorin and radiation therapy for rectal cancer. Oncology. 1997;11:58–60.PubMed
25.
Hoff PM, Janjan N, Saad ED, Skibber J, Crane C, Lassere Y, et al. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol. 2000;18:3529–34.CrossRefPubMed
26.
Feliu J, Calvilio J, Escribano A, de Castro J, Sánchez ME, Mata A, et al. Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy. Ann Oncol. 2002;13:730–6.CrossRefPubMed
27.
Uzcudun AE, Batlle JF, Velasco JC, Sánchez Santos ME, Carpeño Jde C, Grande AG, et al. Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study. Dis Colon Rectum. 2002;45:1349–58.CrossRefPubMed
28.
Kundel Y, Brenner B, Symon Z, Oberman B, Sadezki S, Koller M, et al. A phase II study of oral UFT and leucovorin concurrently with pelvic irradiation as neoadjuvant chemoradiation for rectal cancer. Anticancer Res. 2007;27:2877–80.PubMed
29.
Giralt J, Tabernero J, Navalpotro B, Capdevila J, Espin E, Casado E, et al. Pre-operative chemoradiotherapy with UFT and leucovorin in patients with advanced rectal cancer: a phase II study. Radiother Oncol. 2008;89:263–9.CrossRefPubMed
30.
Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol. 2004;22:3466–74.CrossRefPubMed
31.
Chuah B, Goh BC, Lee SC, Soong R, Lau F, Mulay M, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 2011;102:478–83.CrossRefPubMed
32.
Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27:5124–30.CrossRefPubMedPubMedCentral
33.
Ishihara S, Hayama T, Yamada H, Nozawa K, Matsuda K, Watanabe T. Benefit of tegafur-uracil and leucovorin in chemoradiotherapy for rectal cancer. Hepatogastroenterology. 2011;58:756–62.PubMed
34.
Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17:2396.CrossRefPubMed
35.
Moore HG, Gittleman AE, Minsky BD, Wong D, Paty PB, Weiser M, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum. 2004;47:279–86.CrossRefPubMed
36.
MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457–60.CrossRefPubMed
37.
Sato T, Ozawa H, Hatate K, Onosato W, Naito M, Nakamura T, et al. A phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. Int J Radiat Oncol Biol Phys. 2011;79:677–83. doi:10.​1016/​j.​ijrobp.​2009.​11.​007.CrossRefPubMed
38.
Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamijo A, Murayama C, et al. Phase I/II study of preoperative concurrent chemoradiotherapy with S-1 for locally advanced, resectable rectal adenocarcinoma. Oncology. 2011;81:306–11. doi:10.​1159/​000334580.CrossRefPubMed
39.
Inomata M, Akagi T, Nakajima K, Etoh T, Shiraishi N, Tahara K, et al. Prospective feasibility study to evaluate neoadjuvant-synchronous S-1 + RT for locally advanced rectal cancer: a multicenter phase II trial (UMIN ID: 03396). Jpn J Clin Oncol. 2013;43:321–3. doi:10.​1093/​jjco/​hys219.CrossRefPubMed
40.
Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. Dutch Colorectal Cancer Group. N Engl J Med. 2001;345:638–46.CrossRefPubMed
41.
Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Rectal Cancer Study Group. Cancer. 1990;66:49–55.
42.
Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284:1008–15.CrossRefPubMed
43.
Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol. 2005;23:5620–27.CrossRefPubMed
44.
Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.CrossRefPubMed
45.
Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25:4379–86.CrossRefPubMed
46.
Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–25.CrossRefPubMed
47.
Wang LW, Yang SH, Lin JK, Lin TC, Chan WK, Chen WS, et al. Pre-operative chemoradiotherapy with oral tegafur-uracil and leucovorin for rectal cancer. J Surg Oncol. 2005;89:256–63.CrossRefPubMed
Metadata
Title
Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis
Authors
Ryosuke Nakagawa
Yuji Inoue
Takeshi Ohki
Yuka Kaneko
Fumi Maeda
Masakazu Yamamoto
Publication date
01-12-2017
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2017
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-017-1177-5

Other articles of this Issue 1/2017

World Journal of Surgical Oncology 1/2017 Go to the issue

Case Report

A rare case of intradural and extramedullary epidermoid cyst after repetitive epidural anesthesia: case report and review of the literature

Research

Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis

Research

A comparison of cervical delta-shaped anastomosis and circular stapled anastomosis after esophagectomy

Case Report

Delayed anastomotic leakage following laparoscopic intersphincteric resection for lower rectal cancer: report of four cases and literature review

Technical innovations

Endoscopy-assisted surgery for the management of benign breast tumors: technique, learning curve, and patient-reported outcome from preliminary 323 procedures

Research

Preoperative endoscopic titanium clip placement facilitates intraoperative localization of early-stage esophageal cancer or severe dysplasia